Access event page
Chairpersons: Prof. Francesco Cosentino (ESC), Dr. Subodh Verma (Toronto, CA), Dr Philip Ambery (AstraZeneca), Dr Martin van Eickels (Bayer), Dr Marianne Bach-Treppendahl (Novo Nordisk)
A significant number of patients with cardiovascular disease (CVD) have concomitant metabolic comorbidities which play a causal and/or permissive role in adverse prognosis.
09:00 – 09:10
Welcome – Introduction and objectives of the meeting
09:10 – 09:40
Session I - Common soil and common targets for CKD, NASH and HF?
10 min presentations
The epidemiological basis
Prof. Philip Newsome (Birmingham) - via Zoom
What are the biological underpinnings of the relationship between metabolic and cardiovascular disease?
Prof. Faiez Zannad (Nancy)
What are the clinical and practical implications for physicians as it relates to this interface?
Prof. Per-Henrik Groop (Helsinki)
09:40 – 10:00
10:00 - 10:30
Session II – Unravelling the relationships between obesity and CKD in patients with CV disease
Epidemiology and natural history of this relationship
Prof. Paola Fioretto (Padova)
Obesity and HFpEF – common soil?
Prof. Lars Lund (Stockholm) - via Zoom
Prof. Stefan Anker (Berlin)
10:30 - 10:45
10:45 - 11:05
11:05 - 11:35
Session III - COVID-19: a new threat at the cross-roads between cardiovascular and metabolic diseases
How metabolic derangements affect the incidence and natural history of COVID-19
Prof. Naveed Sattar (Glasgow) - via Zoom
CV derangement in COVID-19
Prof. Scott S. Solomon (Boston)
What are the practical management implications of cardiometabolic disease in patients with COVID-19
Prof. Kamlesh Khunti (Leicester)
11:35 - 12:00
12:00 - 12:15
Session IV - A patient’s perspective on heart failure, renal disease and diabetes.
12:15 - 12:45
12:45 - 13:45
13:45 - 14:15
Session V - Mechanisms of chronic cardiometabolic diseases and opportunities for intervention.
Sex differences in cardiometabolic risk and opportunities for interventionDr. Carolyn Sp Lam (Singapore) - via Zoom
Circulating biomarkers and their utility in cardiometabolic disease
Prof. Andreas M. Zeiher (Frankfurt)
Reversal of Pro-vascular Regenerative Cell Exhaustion in Diabetes and Obesity
Dr. David Hess (Toronto)
14:15 - 14:35
14:35 - 14:55
Lecture – Health and economics consequences of obesityProf. Michele Cecchini (OECD)
Questions to be addressed
14:55 - 16:00
Wrap-up – Next steps – A publication
Our mission: To reduce the burden of cardiovascular disease.
© 2022 European Society of Cardiology. All rights reserved.